QVAR RediHaler® Savings: Savings Card and Insurance Coverage

QVAR REDIHALER Coverage & Reimbursement

Formulary COVERAGE is important to consider

when prescribing asthma MEDICATION

QVAR RediHaler has coverage for more than 80% of patients with commercial insurance^1*

When QVAR RediHaler is covered, this could mean:

Fewer pharmacy callbacks
Less hassle for your staff
Lower co-pays for your insured patients

*As of April 2022.

Patients may be able to save on their

QVAR RediHaler prescriptions

When patients register for the QVAR RediHaler Savings Card, they may save every month.

Eligible insured patients may pay as little as $15 per month on QVAR RediHaler prescriptions.^*
Tell patients they can register for savings by visiting QVAR.com.

For commercially insured patients with coverage for QVAR RediHaler, patients may pay as little as $15 out-of-pocket on each of your patient’s next 12 fills of QVAR RediHaler through December 31, 2022. Teva will pay up to the next $25 of co-payment or cost-sharing obligation per fill. To the extent a commercially insured patient’s cost-sharing obligation on QVAR RediHaler exceeds $40 per fill, the patient is responsible for the remaining balance. Maximum reimbursement limits apply and patient out-of-pocket expenses may vary. Patients are not eligible for this offer if they are eligible to have prescriptions paid for in part or full by any state or federally funded programs, including but not limited to Medicare, Medicaid, Medigap, VA, DOD, TRICARE, or by private health benefit programs which reimburse you for the entire cost of your prescription drugs.

Discover resources for your patients

Important Safety Information

Contraindications: QVAR RediHaler is contraindicated in:
- Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required
- Patients with known hypersensitivity to beclomethasone dipropionate or any of the ingredients in QVAR RediHaler
Oropharyngeal Candidiasis: Localized infections with Candida albicans have occurred in the mouth and pharynx in some patients receiving QVAR RediHaler. Advise rinsing of mouth with water without swallowing after use. If oropharyngeal candidiasis develops, QVAR RediHaler may need to be temporarily interrupted under close medical supervision
Deterioration of asthma and acute episodes: Do not use QVAR RediHaler for the relief of acute symptoms. Instruct patients to contact their physician immediately if episodes of asthma that are not responsive to bronchodilators occur during the course of treatment with QVAR RediHaler
Transferring Patients from Systemic Corticosteroid Therapy: Particular care is needed in patients who are transferred from systemically active corticosteroids to QVAR RediHaler because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids. Taper patients slowly from systemic corticosteroids if transferring to QVAR RediHaler
Immunosuppression and Risks of Infections: Patients who are on drugs that suppress the immune system, such as corticosteroids, are more susceptible to infections than healthy individuals and should avoid exposure to chicken pox or measles. Inhaled corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infection of the respiratory tract; untreated systemic fungal, bacterial, parasitic, or viral infections; or ocular herpes simplex
Paradoxical Bronchospasm: Inhaled corticosteroids may produce inhalation-induced bronchospasm with an immediate increase in wheezing after dosing that may be life-threatening. If this occurs with QVAR RediHaler, it should be treated immediately with an inhaled, short-acting bronchodilator. Treatment with QVAR RediHaler should be discontinued and alternate therapy instituted
Hypersensitivity reactions: Hypersensitivity reactions, such as urticaria, angioedema, rash, and bronchospasm, may occur after administration of QVAR RediHaler. Discontinue QVAR RediHaler if such reactions occur
Hypercorticism and Adrenal Suppression: It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression may appear in a small number of patients, particularly at higher than recommended doses. If such changes occur, reduce the QVAR RediHaler dose slowly, consistent with accepted procedures for reducing systemic corticosteroids and for management of asthma symptoms
Effects on Growth: Orally inhaled corticosteroids, including QVAR RediHaler, may cause a reduction in growth velocity when administered to pediatric patients. Routinely monitor the growth of pediatric patients receiving QVAR RediHaler. To minimize the systemic effects, titrate to the lowest dosage that effectively controls symptoms
Reduction in Bone Mineral Density (BMD): Decreases in bone mineral density have been observed with long-term administration of products containing inhaled corticosteroids. Patients with major risk factors for decreased bone mineral content should be monitored and treated with established standards of care
Glaucoma and Cataracts: Glaucoma, increased intraocular pressure, blurred vision and cataracts have been reported following the long-term administration of inhaled corticosteroids. Therefore, close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure, blurred vision, glaucoma, and/or cataracts
Adverse Reactions: Most common adverse reactions (incidence ≥3% and >placebo) include oral candidiasis, upper respiratory tract infection, nasopharyngitis, allergic rhinitis, oropharyngeal pain and sinusitis.

Indication

QVAR RediHaler is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 4 years of age or older.

Limitation of Use: QVAR RediHaler is not indicated for the relief of acute bronchospasm.

Please see full Prescribing Information.